IN8bio Reports Strong Glioblastoma Data but Faces Cash Burn Challenge
Event summary
- IN8bio reported median overall survival exceeding 19.5 months in glioblastoma patients treated with DeltEx™ DRI, compared to 13.2 months for standard-of-care.
- Peer-reviewed data in The Journal of Clinical Oncology showed no dose-limiting toxicities or cytokine release syndrome in GBM patients.
- INB-619, a CD19-targeting γδ T cell engager, advanced into IND-enabling studies with promising preclinical data.
- Cash position stood at $18.0 million as of June 30, 2026, down from $27.0 million in December 2025.
The big picture
IN8bio's updated clinical data for DeltEx™ DRI in glioblastoma reinforces the potential of γδ T cell therapies, but the company must navigate a tight cash position and secure regulatory clarity to advance its pipeline. The biotech sector is increasingly focused on innovative cancer treatments, and IN8bio's ability to differentiate itself through its proprietary platform will be key to its long-term success.
What we're watching
- Regulatory Pathway
- Whether IN8bio can secure FDA guidance on a regulatory pathway for DeltEx™ DRI in glioblastoma, which is critical for future approval.
- Cash Sustainability
- The pace at which IN8bio burns through its remaining $18.0 million cash position and whether it can secure additional funding.
- Clinical Validation
- How initial in vivo data for INB-619 in the second half of 2026 will impact investor confidence in the company's next-generation γδ TCE platform.
Related topics